Close Menu

modeling

In PLOS this week: computational tool to uncover selection within populations, sequencing-based analysis of canine lymphoma, and more.

Regular SARS-CoV-2 testing could limit COVID-19 cases on university campuses but results might vary based on the schools' behavioral interventions.

An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.

At the second virtual session of the AACR annual meeting, researchers also discussed how they're using CRISPR to develop better cancer models and reprogram T cells.

Launched in 2016 by researchers in Utah, the firm recently published a genome-wide signature that predicts survival of glioblastoma patients. 

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

Alterations that arise that have high fitness are also associated with an increased risk of developing acute myeloid leukemia.

An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.

Genes influencing NOTCH pathway activity were linked to head and neck squamous cell carcinoma with a mouse screen centered on genes with long tail mutations in human cases.

ZPredicta's platform is designed to integrate organ-specific cellular and extracellular elements into 3D culture models for in vitro cancer drug testing.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.